This trial is evaluating whether Core-g28v2 60mer mRNA Vaccine will improve 1 primary outcome, 1 secondary outcome, and 1 other outcome in patients with Hiv. Measurement will happen over the course of 9 months.
This trial requires 56 total participants across 4 different treatment groups
This trial involves 4 different treatments. Core-g28v2 60mer MRNA Vaccine is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
"Commonly prescribed treatment for HIV in Italy are antiretroviral drugs (mostly Nucleoside Reverse Transcriptase Inhibitor drugs) and prophylactic therapy. There is a lack of information in regards to therapy in Italy." - Anonymous Online Contributor
"HIV is an illness caused by a virus and is a significant risk factor for many diseases. It is an illness that kills about 50 million people each year. Worldwide, more than 40 million people are living with HIV and about 2 million people are being new infected each year.\n" - Anonymous Online Contributor
"Around 440,000 new HIV infections are confirmed each year in the United States. Although less than 10% of those diagnosed as HIV carriers become symptomatic, around 25% of those infected with HTLV-1 become symptomatic. While HIV treatment has led to significant reductions in AIDS-related mortality, new infections have not been reduced drastically and remain a major public health problem. The AIDS epidemic in America should be considered a slow wave to a more destructive pandemic. This paper is an attempt to explain how such a pandemic could occur, especially in a country with an effective health protection system like the United States." - Anonymous Online Contributor
"The majority of HIV infection worldwide can be attributed to three main routes of HIV transmission: sexual contact, injection of contaminated blood as intravenous drug use, and vertical transmission or mother-to-child transmission of HIV. In some countries, however, HIV infection disproportionately affects women, and certain non-Western groups of men. To understand what role biomedical HIV prevention research might play, we focus on the impact of these three routes on the overall risk of HIV transmission, and on specific risk factors that play a more role in transmission by one route than another. Understanding the role of these risk factors will help in developing policies and strategies to reduce HIV risk overall among individuals, populations, and communities." - Anonymous Online Contributor
"About 60% to 76% of hiv patients can be cured once the infection is detected. This is true even if the disease has progressed to a stage in its course at the time of treatment. A cure of hiv does not mean the total suppression of all signs and symptoms. The possibility of cure of the virus and of the disease must be evaluated together with the patient's individual treatment needs. With HAART the incidence of AIDS has decreased significantly, and thus patients diagnosed before the advent of HAART are less likely to present with advanced disease. Therefore, the majority of hiv patients could be cured by early, high-dose combination antiretroviral therapy." - Anonymous Online Contributor
"Signs of HIV are fatigue, malaise and weight loss. Although it may be difficult to notice or to relate these features with the symptoms, awareness and prompt recognition and management of HIV can greatly improve the outlook for affected patients." - Anonymous Online Contributor
"Results from a recent clinical trial showed that both core-g28v2 60mer and core-g28v3 60mer can induce immune response and show some limited antiviral activity in mice which can be explained by the core-g28v2 60mer 60mer sequence of the HCV genome. The immune response after vaccination with core-g28v2 60mer has some antiviral activity in mice after inoculation with HCV core-g28v2 60mer, but there is no effect after inoculation with HCV core-g28v3 60mer." - Anonymous Online Contributor
"This raises the disturbing possibility that the HIV in the German population may be run-in with a genetic propensity for the virus. Such a genetic predisposition could explain many previously unexplained and unexplainable patterns in the incidence of AIDS and may be potentially important for further investigations in related populations." - Anonymous Online Contributor
"The average age someone gets hiv is 21.2 years. The majority of people getting in touch with this disease is between ages of 17 and 24 years. Many HIV positive persons fail to disclose their age when they get tested for HIV. This may be due to the fact that they feel bad about being labeled HIV positive. The older person gets diagnosed at, the more severe the illness is. This also indicates increased risk of death.\n" - Anonymous Online Contributor
"The immune-response elicited by CAG-HIV60mer vaccination is likely improved by combination with a broad-spectrum adjuvant and a T-helper epitope. This vaccine may therefore be suitable for use in the context of future HIV-1 vaccination strategies." - Anonymous Online Contributor
"The new drugs for treating HIV are more effective but are also far more dangerous than older medication. Because treatment is becoming more effective each year, it is possible that the chance of a cure will slip away. There are many factors involved, but a major one is that scientists and clinicians have far more information available about HIV than when they began their research. More information is available about treatment than about how HIV is transmitted and how it will be managed after treatment." - Anonymous Online Contributor
"The safety of the vaccine is acceptable after the review of the vaccination records of a large cohort of individuals. The most common side-effects in our population consisted with fever (>38.3 °C) in 11.2% of the vaccinated cohort. Drowsiness (0.6%) and nausea (>5%) occurred in 2.4% of the vaccinated cohort." - Anonymous Online Contributor